Circulation Journal · Nov 17, 2026
Heart Failure Beyond Valve Treatment ― Mechanisms, Predictors, and Therapeutic Strategies After Transcatheter Aortic Valve Replacement ―
By Kitahara H, Matsuura K, Kobayashi Y
Transcatheter aortic valve replacement (TAVR) has become an established treatment for severe aortic stenosis across the spectrum of surgical risk, substantially improving symptoms and clinical outcomes. However, heart failure (HF) remains a major cause of hospitalization and mortality after TAVR, indicating that relief of valvular stenosis alone may not completely eliminate HF risk. HF after TAVR is multifactorial, reflecting residual cardiac damage and incomplete reverse remodeling, concomitant cardiovascular abnormalities, procedure- and prosthesis-related factors, underlying HF substrate, and systemic comorbidities. Importantly, both the baseline extent of cardiac damage and its persistence after TAVR are associated with adverse outcomes, highlighting the importance of serial assessment beyond procedural success. In addition, many patients undergoing TAVR are elderly and have features of HF with preserved ejection fraction, which may contribute to persistent HF despite successful valve intervention. Emerging evidence, including randomized trial data on sodium–glucose cotransporter 2 inhibitors, suggests that targeted pharmacological therapy may reduce residual HF risk after TAVR. In this review we summarize the epidemiology, clinical impact, mechanisms, risk stratification, and management of HF after TAVR, and discuss future strategies for its prevention and treatment.
doi.org/10.1253/circj.cj-26-1049Open accessPowered by J-STAGEMechanisms